Cancerous cells harvested from adult patients respond well to combination blood and cell transfusion with preclinical cells according to preclinical studies led by UT Health San Antonios Ken Czepnik MD PhD Lyle Petersen and John S. Dearani Associate Professor of Radiation Oncology. Leukemia is a poorly understood subset of cancers with harmful DNA damage that progress through multiple stages and that frequently recur in adult patients. The clinical implications of these observations are that the adjuvant therapy used for leukemias may need to be carefully targeted to avoid toxic side-effects.

The study was conducted at Chemochemistry for LEU a Burn Policy Research Institute-led clinic that treats patients with acute myeloid leukemia the most common type of adult cancer. The study Malignant behavior defects revealed by chemo-transfusion in patients with acute myeloid leukemia was published in The Journal of Clinical Investigation.

Cancer cells pay close attention to structure and functional properties. . . Leonardo Nardi MD an Associate Professor at UT Health San Antonio became interested in the topic after reading research papers with the title Leukemic cells: sophisticated organoid constructions using primary tumor biopsies and secondary information on the metabolic life cycle and mutation dynamics of leukemia cells in 1985. I have often had the pleasure of working with Dr. Nardi who compared the components of this organoid to the organoids used in reconstructive surgery says Dr. Nardi.

Nardi anticipates that the treatment strategies for leukemias given the present results and for leukemia targeted with the experimental immunotherapy agent NSAID1pemetrexed will be expanded to include improved prognosis and improved clinical placidity as compared to preclinical models in leukemic patients.